Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprorelin and Sintilimab in Advanced Lung Cancer
NCT06512207Recruiting
- Sponsor
- Jinzhou Medical University
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of leuprolide in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jinzhou Medical University. Primary endpoints: Complete Response at 18 weeks, Partial Response at 18 weeks and 5 more. Started Dec 2023; status: recruiting.
02
Drugs
leuprolide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06512207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06512207.